Medicum Rosenheim MVZ GmbH

The department targets neoplastic conditions, with a special emphasis on hormone receptor‑positive, HER2‑negative early breast cancer, seeking to lower recurrence through novel therapeutic approaches.

• Assessing the impact of targeted endocrine therapy
• Implementing patient‑centered education to boost treatment persistence
• Monitoring time to permanent discontinuation of therapy

At Medicum Rosenheim MVZ GmbH, investigators combine drug evaluation with coaching programs to extend the benefit of treatments such as ribociclib.

The site’s oncology program investigates advanced colorectal carcinoma, comparing innovative combination regimens to improve first‑line effectiveness in patients with metastatic disease.

• Testing trifluridine/tipiracil with panitumumab versus bevacizumab
• Evaluating overall response and progression‑free survival
• Optimizing therapeutic choices for metastatic patients

Research conducted at Medicum Rosenheim MVZ GmbH aims to refine treatment selection and enhance outcomes for individuals facing advanced colorectal cancer.